The spectrum of Progressive Familial Intrahepatic Cholestasis diseases: Update on pathophysiology and emerging treatments
- 1 November 2021
- journal article
- research article
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 64 (11) , 104317
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2Journal of Hepatology, 2012
- Mutation specific drug therapy for progressive familial or benign recurrent intrahepatic cholestasis: A new tool in a near future?Journal of Hepatology, 2010
- Differences in presentation and progression between severe FIC1 and BSEP deficienciesJournal of Hepatology, 2010
- ATP8B1 is essential for maintaining normal hearingProceedings of the National Academy of Sciences, 2009
- Progressive familial intrahepatic cholestasisOrphanet Journal of Rare Diseases, 2009
- Positional Cloning of “Lisch-like”, a Candidate Modifier of Susceptibility to Type 2 Diabetes in MicePLOS Genetics, 2008
- Severe Bile Salt Export Pump Deficiency: 82 Different ABCB11 Mutations in 109 FamiliesGastroenterology, 2008
- 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumpsHepatology, 2007
- Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11†Hepatology, 2005
- Distribution of the lipolysis stimulated receptor in adult and embryonic murine tissues and lethality of LSR–/– embryos at 12.5 to 14.5 days of gestationEuropean Journal of Biochemistry, 2004